Improvement in HbA1c in patients with type 2 diabetes with Humalog® Mix 25 versus basal human insulin: A double-blind study

Journal of Applied Therapeutic Research

Volumn 4, Issue 4, 2004, Pages 19-26

  Malone, J K ^a   Wolthers, T ^a   Sun, B ^a   Gulliya, K ^a   Mattoo, V ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

HbA1c; Humalog Mix25; HumaPen Ergo; NPH; Type 2 diabetes

Indexed keywords

EID: 14844365169     PISSN: 10292659     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. American Diabetes Association Staff (2002). Practical Insulin - A Handbook for Prescribers. Alexandria, VA. American Diabetes Association, pp. 36-40.
2. Bell, D. S. (2001). Importance of postprandial glucose control. Southern Medical Journal, 94, 804-809.
3. Coppack, S. W. (1997). Postprandial lipoproteins in noninsulin-dependent diabetes mellitus. Diabetic Medicine, 14, S67-S74.
4. Deeb, L. C., Holcombe, J. H. et al. (2001). Insulin lispro lowers postprandial glucose in prepubertal children with diabetes. Pediatrics, 108, 1175-1179.
5. Festa, A., D'Agostino, R. et al. (1999). Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: The Insulin Resistance Atherosclerosis Study (IRAS). Arteriosclerosis, Thrombosis, and Vascular Biology, 19, 562-568.
6. Grizzle, J. E. (1965). The two-period change-over design and its use in clinical trials. Biometrics, 21, 467-480.
7. Koch, G. G. (1972). The use of nonparametric methods in statistical analysis of the two-period change-over design. Biometrics, 8, 577-584.
8. Mudalair, S. R. D. and Edelman, S. V. (2000). Intensive Insulin Therapy for Patients with Type 2 Diabetes Mellitus. In: Diabetes Mellitus, A Fundamental and Clinical Text. LeRoith, D., Taylor, S. I. & Olefsky, J. M., Eds. Philadelphia, PA. Lippincott Williams & Wilkins, pp. 811-827.
9. Radziuk, J., Bradley, B. et al. (1996). Profiles of biological activity after subcutaneous administration of mixtures of LysB28-ProB29 human insulin (lispro) in soluble and neutral protamine formulations. Diabetes, 5, (Suppl 2) 218A.
10. Roach, P., Strack, T. et al. (2001). Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. International Journal of Clinical Practice, 55, 177-182.
11. Roach, P., Trautmann, M. et al. (1999a). Improved postprandial blood glucose control and reduced nocturnal hypoglycaemia during treatment with two novel insulin lisproprotamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. Clinical Therapeutics, 21, 523-534.
12. Roach, P., Yue, L. et al. (1999b). Improved postprandial glycaemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care, 22, 1258-1261.
13. Stratton, I. M., Adler, A. I. et al. (2000). Associations of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal, 321, 405-412.
14. Taulbee, J. D. (1982). A note on the use of nonparametric methods in the statistical analysis of the two-period changeover design. Biometrics, 38, 1053-1055.
15. UK-Prospective Diabetes Study Group (1998). UK Prospective Diabetes Study 33: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet, 352, 837-853.
16. Yki-Jarvinen, H. (2001). Combination Therapies with Insulin in Type 2 Diabetes. Diabetes Care, 24, 758-767.